Liquid or dry prebiotic formulation for oral administration to a human, containing (a) 0.5-2 mg / ml of 2'-fucosyl-lactose and 1-4 mg / ml of 3'-sialyl-lactose and 0.5 -2 mg / ml of 6'-sialyl-lactose, when said formulation is liquid, or (b) at least 0.4% ep of 2'-fucosyl-lactose and at least 0.8% e.p. of 3'-sialyl-lactose and at least 0.4% e.p. of 6'-sialyl-lactose, when said formulation is a dry powder.Formulación prebiótica líquida o seca para administración oral a un humano, que contiene (a) 0,5-2 mg/ml de 2'-fucosil-lactosa y 1-4 mg/ml de 3'-sialil-lactosa y 0,5-2 mg/ml de 6'-sialil-lactosa, cuando dicha formulación es líquida, o (b) al menos 0,4% e.p. de 2'-fucosil-lactosa y al menos 0,8% e.p. de 3'-sialil-lactosa y al menos 0,4% e.p. de 6'-sialil-lactosa, cuando dicha formulación es un polvo seco.
